Eli Lilly and Company
LLY · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.65 | -8.88 | 4.52 | -4.92 |
| FCF Yield | 0.06% | -0.60% | 1.32% | 2.05% |
| EV / EBITDA | 47.65 | 63.81 | 41.77 | 34.38 |
| Quality | ||||
| ROIC | 26.36% | 19.77% | 23.45% | 20.38% |
| Gross Margin | 81.31% | 79.25% | 76.77% | 74.18% |
| Cash Conversion Ratio | 0.83 | 0.81 | 1.21 | 1.32 |
| Growth | ||||
| Revenue 3-Year CAGR | 16.43% | 6.41% | 5.16% | 8.26% |
| Free Cash Flow Growth | 113.14% | -168.52% | -14.61% | 20.51% |
| Safety | ||||
| Net Debt / EBITDA | 1.99 | 2.62 | 1.64 | 1.62 |
| Interest Coverage | 22.42 | 22.20 | 26.10 | 23.35 |
| Efficiency | ||||
| Inventory Turnover | 1.11 | 1.23 | 1.54 | 1.88 |
| Cash Conversion Cycle | 296.64 | 284.84 | 240.44 | 215.33 |